LDL cholesterol: oral PCSK9 inhibitors show a substantial effect, but evidence remains limited

Five trials comparing treatments with placebo

The systematic review, dated October 6, 2026 in the dossier, brings together five randomized trials involving 4,227 participants. The researchers searched four databases through May 1, 2026. Three oral agents were studied: two peptide-based agents and one small molecule.

The network meta-analysis distinguishes twelve drug–dose combinations. Its primary outcome is the percentage change in LDL from the start of treatment, compared with that observed with placebo. The dossier provides only the PubMed abstract, not the full text.

Lower LDL, not proof of cardiovascular benefit

All twelve combinations reduce LDL compared with placebo. For NNC0385-0434 at the studied dose of 100 mg, the mean difference in change reaches −61.8 percentage points, with a 95% confidence interval from −78.1 to −45.5 points. This figure describes a difference between groups, not a guaranteed reduction for each patient.

A dose–response relationship is reported for all three agents. However, the results presented concern lipid parameters and achievement of LDL targets. On their own, they do not demonstrate a reduction in heart attacks, strokes or mortality.

The ranking of the agents remains uncertain

A statistical ranking cannot identify a best treatment here. The 51 comparisons between different agents are entirely indirect: they rely on comparisons with placebo rather than trials directly comparing the agents.

None of the six comparisons between the four highest-ranked doses is statistically significant. The uncertainty intervals for the rankings overlap. Heterogeneity in the results is also substantial, although it disappears in the analysis at the 24-week assessment point. The authors rate the overall certainty of the evidence as low.

Long-term safety remains to be established

No short-term safety signal was detected in the included trials. This means neither an absence of adverse effects nor proven safety with prolonged use.

The abstract provided does not detail the duration of each trial, excluded populations, interactions or adverse events. Funding and conflicts of interest could not be verified in this dossier. These results also provide no information about possible approval or availability in France.

What we can take away

These oral treatments show a substantial effect on LDL compared with placebo. However, the data presented do not allow a superior agent to be identified or conclusions to be drawn about cardiovascular benefit or long-term safety.